Buying guide
Lingo vs Happy Ring in 2026
Comparing 2 humanoid robots across availability, pricing, capabilities, and verified deployments. Current as of 2026.
| Attribute | No image on file | No image on file |
|---|---|---|
| Manufacturer | Abbott | Happy Health |
| Form factor | biometric | biometric |
| Maturity | commercial | commercial |
| Availability | shipping-nowshipping | internal-onlyenterprise |
| Price | $54 (actual sale price) | Not announced |
| Capability claims | — | — |
| Brain | — | — |
| Verified deployments | 1Abbott | 0 |
| Privacy practices | 4third-party-sharing, data-deletion-control, biometric-storage, training-data-use | — |
| Sources on file | 8 | 7 |
Editorial summaries
Lingo
Abbott's Lingo is an over-the-counter continuous glucose monitor for non-diabetic and wellness consumers, built on Abbott's FreeStyle Libre sensor platform (FDA 510(k) K233655, decided May 29, 2024; Class II integrated CGM): a disposable biosensor worn up to 14 days on the back of the upper arm. It is the adaptive-algorithmic end of the glucose cell, the documented contrast to Stelo's generative AI: the app's 'Lingo Count' daily glucose-spike metric with adaptive targets, food and activity logging, and rule-based personalized recommendations are adaptive-algorithmic, not generative. 'Lingo Live' is free roughly 30-minute sessions with human Abbott nutritionists, not an AI coach, and DEPLOY surfaces that distinction prominently. Pricing starts at about $54 for a 2-week single-biosensor plan, with recurring biweekly and monthly multi-sensor tiers. From Abbott (NYSE: ABT). Cap-flag: the cleared indication is adults 18+ not on insulin, explicitly NOT for diagnosis of any disease including diabetes.
Happy Ring
The Happy Ring (from Happy Health Inc, Austin, Texas; CEO Dustin Freckleton, MD) is the FDA-cleared, service-gated archetype of the ring sub-cohort, and the sharpest verified-vs-claimed counterpoint to RingConn: the same finger-ring form factor and similar sleep-apnea capability claims, but a diametrically opposite verification posture. Its cleared sleep-apnea algorithm is the regulatory substance, with two dated FDA 510(k) clearances: K240236 (October 8, 2024) for retrospective remote monitoring of physiological parameters in adults at home or in healthcare facilities; and K242224 (June 18, 2025) for a Home Sleep Test that processes the ring's signals for clinician-interpreted diagnosis of sleep disorders such as obstructive sleep apnea and insomnia, ages 22+, under the direction of a trained healthcare provider (clinician-directed, not autonomous diagnosis). It is not a standalone retail ring: it is sold only bundled into the clinician-reviewed, insurer-billed 'Happy Sleep' home-sleep-test service, so there is no published consumer price. Cap-flags: a 97% agreement with polysomnography is company-reported with no peer-reviewed citation; the 'brain biometrics' marketing is not substantiated by any named EEG hardware; and funding is a $60M Series A (August 2022, ARCH Venture Partners) with no later round surfaced, an early-stage state.
Machine-readable: this page as markdown.